Announcements Trials
Browse Landscape

Phase

Phase 1 5Phase 2 2Phase 3 1Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Neoplasm Metastasis 8Colorectal Neoplasms 7Lung Neoplasms 6Prostatic Neoplasms 5Melanoma 5Carcinoma, Hepatocellular 5Triple Negative Breast Neoplasms 4Ovarian Neoplasms 4Multiple Myeloma 4Fallopian Tube Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Pancreatic Neoplasms 3Lymphoma, Mantle-Cell 3Leukemia, Myeloid, Acute 3Carcinoma, Renal Cell 3Sarcoma 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Myelodysplastic Syndromes 2Meningioma 2Lymphoma, Large B-Cell, Diffuse 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Biphenotypic, Acute 2Glioblastoma 2Gastrointestinal Neoplasms 2Endometrial Neoplasms 2Colonic Neoplasms 2Cholangiocarcinoma 2Carcinoma, Transitional Cell 2Carcinoma, Merkel Cell 2

Interventions

Peripheral Blood Stem Cell Transplantation 5Cyclophosphamide 5romidepsin 4pembrolizumab 4Lenalidomide 4Etoposide 410-propargyl-10-deazaaminopterin 4Rituximab 3fludarabine phosphate 2fludarabine 2durvalumab 2carmustine, poliferprosan 20 drug combination 2Vincristine 2Prednisone 2N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 2Melphalan 2Gemcitabine 2Doxorubicin 2Depsipeptides 2Cytarabine 2Carmustine 2Bendamustine Hydrochloride 2AFM13 2veliparib 1thymoglobulin 1tenalisib 1temsirolimus 1prednylidene 1mogamulizumab 1forodesine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Lymphoma, T-Cell × Specimen Handling × Clear all
NCT07225985 2026-05-11

Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma

Fred Hutchinson Cancer Center

Phase 1/2 Recruiting
50 enrolled
Lymphoid

Lymphoma, T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡